46 results on '"Wildes, Tanya M."'
Search Results
2. A real‐world data analysis of predictors of early mortality after a diagnosis of multiple myeloma.
- Author
-
Grant, Shakira J., Wildes, Tanya M., Rosko, Ashley E., Silberstein, Juliet, and Giri, Smith
- Subjects
- *
MULTIPLE myeloma , *OLDER patients , *OLDER people , *SURVIVAL rate , *DATA analysis , *RENOVASCULAR hypertension , *PLASMACYTOMA - Abstract
Background: Despite the increased availability and use of novel therapies for multiple myeloma, early mortality is a pervasive challenge with a significant impact on older adults. Reported rates and predictors of early mortality have varied in the literature, with most studies seldom focusing on community‐treated patients. Methods: In this retrospective cohort analysis of a real‐world electronic health record–derived deidentified database of 7512 patients newly diagnosed with multiple myeloma between January 1, 2011, and February 2, 2021, and treated primarily in US‐based community oncology practices, factors associated with early mortality (defined as death within 6 months after the multiple myeloma diagnosis) were examined with the use of binary logistic regression. Results: The median age was 70 years overall. We found an overall early mortality rate of 8.3%, with 73% of early deaths occurring in those aged ≥70 years. Among the early deaths, only 49 patients (8.7%) had documented disease progression before death (median time to progression, 30 days [interquartile range, 7–53 days]). Baseline factors associated with higher odds of early mortality included an Eastern Cooperative Oncology Group performance status (ECOG PS) ≥ 2, Revised International Staging System (R‐ISS) stage III, an age ≥ 70 years, receipt of proteasome inhibitor–doublet therapy, a light‐chain isotype, and the presence of renal dysfunction (estimated glomerular filtration rate < 30 mL/min). Among those aged ≥70 years, ECOG PS ≥ 2 and R‐ISS stage III remained the strongest predictors of early mortality. Conclusions: Early mortality disproportionately affects older adults (aged ≥70 years) with multiple myeloma. Interventions to support this population are needed to reduce disparate survival outcomes. Plain language summary: Factors associated with an increased risk of dying within 6 months (early mortality) of a new diagnosis of multiple myeloma (MM) among 7512 mostly community‐treated patients with MM were evaluated.The early mortality rate was 8.3%; among those deaths, 49 patients (8.7%) had documented evidence of MM progression before death.The risk of early mortality was greatest for older patients (aged ≥70 years) and those with a poor performance status, poor kidney function, a higher disease stage, and light‐chain MM and those receiving two‐drug MM therapies.These findings highlight the need for supportive interventions geared toward older adults with MM. Approximately 9% of adults newly diagnosed with multiple myeloma will die within 6 months. Most early deaths occur in those aged 70 years or older and among those with advanced disease, a poor performance status, and kidney dysfunction and those who have received a proteasome inhibitor‐based doublet regimen. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Geriatric Assessment in Older Adults with Multiple Myeloma.
- Author
-
Wildes, Tanya M., Tuchman, Sascha A., Klepin, Heidi D., Mikhael, Joseph, Trinkaus, Kathryn, Stockerl‐Goldstein, Keith, Vij, Ravi, and Colditz, Graham
- Subjects
- *
GERIATRIC assessment , *MULTIPLE myeloma , *CANCER patients , *MEDICAL examinations of older people , *HEMATOPOIETIC stem cell transplantation - Abstract
BACKGROUND/OBJECTIVES: The incidence of myeloma in older adults is increasing, yet little is known about geriatric impairments in these patients. We aimed to examine the prevalence of geriatric impairments in older adults with myeloma and the association between geriatric assessment and autologous stem cell transplant eligibility. DESIGN: Prospective cohort study. SETTING: Two academic medical centers. PARTICIPANTS: A total of 40 adults 65 years and older with newly diagnosed myeloma were enrolled. MEASUREMENT: Participants completed a primarily self‐administered geriatric assessment, including measures of functional status, comorbidities, polypharmacy, psychosocial status, social support, quality of life, cognition, and physical performance. Outcomes were autologous stem cell transplant eligibility and receipt. RESULTS: Forty patients enrolled; their mean age was 71 years. Geriatric impairments were common: 62% reported dependence in one or more instrumental activities of daily living (IADL), 76.9% had polypharmacy (four or more medications), and 47.5% had one or more comorbidities. Median time on the Timed Up and Go was 13.3 ± 4.9 seconds. Those considered candidates for autologous stem cell transplant (N = 26) were younger, with fewer comorbidities, better performance status, and faster performance on the Timed Up and Go test. Factors independently associated with receiving autologous stem cell transplant (N = 21) included age and IADL dependence. CONCLUSION: Impairments in geriatric domains are common in this population, even among those considered to have a good performance status. Geriatric assessment domains are associated with both transplant eligibility and receipt. J Am Geriatr Soc 67:987–991, 2019. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
4. Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group.
- Author
-
Wildes, Tanya M., Maggiore, Ronald J., Tew, William P., Smith, David, Sun, Can-Lan, Cohen, Harvey, Mohile, Supriya G., Gajra, Ajeet, Klepin, Heidi D., Owusu, Cynthia, Gross, Cary P., Muss, Hyman, Chapman, Andrew, Lichtman, Stuart M., Katheria, Vani, Hurria, Arti, On behalf of the Cancer and Aging Research Group, and Cancer and Aging Research Group
- Subjects
- *
ACCIDENTAL falls in old age , *CANCER patients , *GERIATRICS , *MULTIVARIATE analysis , *POLYPHARMACY , *AGE distribution , *GERIATRIC assessment , *AGING , *ACCIDENTAL falls , *LONGITUDINAL method , *MATHEMATICAL models , *RESEARCH methodology , *RESEARCH funding , *TUMORS , *COMORBIDITY , *THEORY , *DISEASE prevalence , *CROSS-sectional method , *DISEASE complications - Abstract
Background: Falls in older adults with cancer are common, yet factors associated with fall-risk are not well-defined and may differ from the general geriatric population. This study aims to develop and validate a model of factors associated with prior falls among older adults with cancer.Methods: In this cross-sectional secondary analysis, two cohorts of patients aged ≥ 65 with cancer were examined to develop and validate a model of factors associated with falls in the prior 6 months. Potential independent variables, including demographic and laboratory data and a geriatric assessment (encompassing comorbidities, functional status, physical performance, medications, and psychosocial status), were identified. A multivariate model was developed in the derivation cohort using an exhaustive modeling approach. The model selected for validation offered a low Akaike Information Criteria value and included dichotomized variables for ease of clinical use. This model was then applied in the validation cohort.Results: The development cohort (N = 498) had a mean age of 73 (range 65-91). Nearly one-fifth (18.2%) reported a fall in the prior 6 months. The selected model comprised nine variables involving functional status, objective physical performance, depression, medications, and renal function. The AUC of the model was 0.72 (95% confidence intervals 0.65-0.78). In the validation cohort (N = 250), the prevalence of prior falls was 23.6%. The AUC of the model in the validation cohort was 0.62 (95% confidence intervals 0.51-0.71).Conclusion: In this study, we developed and validated a model of factors associated with prior falls in older adults with cancer. Future study is needed to examine the utility of such a model in prospectively predicting incident falls. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
5. Development of a Medicare Health Outcomes Survey Deficit-Accumulation Frailty Index and Its Application to Older Patients With Newly Diagnosed Multiple Myeloma.
- Author
-
Mian, Hira S., Wildes, Tanya M., and Fiala, Mark A.
- Subjects
- *
OLDER patients , *MULTIPLE myeloma , *FRAGILITY (Psychology) , *MEDICARE , *AGE - Abstract
Purpose: To develop a frailty index using the Rockwood Accumulation of Deficits approach for the Medicare Health Outcomes Survey (MHOS) and apply it in a subset of older patients with newly diagnosed multiple myeloma. Methods: Data from 2,692,361 patients without cancer, > 66 years of age, in SEER-MHOS linked databases between 1998 and 2009 were analyzed. A frailty index was constructed, resulting in a 25-item scale; cutoff values were created for individuals classified as frail. This frailty index was then applied to 305 patients with newly diagnosed myeloma in the database to predict overall survival. Results: In the derivation cohort of patients without cancer, the median age was 74 years and the mean frailty index was 0.23 (standard deviation, 0.17). Among patients without cancer, each 10% increase in frailty index (approximately three to four more deficits) was associated with a 40% increased risk for death (adjusted hazard ratio, 1.397; 95% CI, 1.396 to 1.399; P <.001). In the cohort of patients with newly diagnosed myeloma, the median age was 76 years an d the mean frailty index was 0.28 (standard deviation, 0.17). Each 10% increase in frailty index was associated with a 16% increased risk for death (adjusted hazard ratio, 1.159; 95% CI, 1.080 to 1.244; P <.001). Fifty-three percent of patients with multiple myeloma were considered frail. The estimated median overall survival of patients considered frail was 26.8 months, compared with 43.7 months ( P =.015) for those who were not. Conclusion: The MHOS-based frailty index was prognostic for patients with multiple myeloma in predicting overall survival. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
6. Novel Treatments for Multiple Myeloma: What Role Do They Have in Older Adults?
- Author
-
Mian, Hira S. and Wildes, Tanya M.
- Subjects
- *
DRUG therapy , *CLINICAL trials , *DRUG toxicity , *MULTIPLE myeloma , *OLD age , *PREVENTION - Abstract
Multiple myeloma is a malignant plasma cell disease, which typically affects older patients, with a median age at diagnosis of 70 years. The recent introduction of novel drugs and ongoing improvements in supportive care have significantly contributed to overall better management and outcomes for patients with multiple myeloma. Autologous stem-cell transplantation has been a standard part of therapy for myeloma patients for many years, first in younger patients and increasingly in older, and may still be considered in selected older patients with myeloma. In addition, in both newly diagnosed patients and in the relapsed/refractory setting, a number of novel agents tested in large phase III trials have yielded improvements in overall outcomes. As clinical trials under-enrol older patients and have stringent exclusion criteria, the data and results from them may not be generalizable to all older adults. In this review, we examine the treatment options for older adults with myeloma with a specific focus on the currently available data on novel agents in this cohort. The clinical efficacy and unique toxicity profile of each novel agent must be considered prior to the treatment plan in older adults. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
7. Falls in older adults with multiple myeloma.
- Author
-
Wildes, Tanya M. and Fiala, Mark A.
- Subjects
- *
MULTIPLE myeloma , *PRIMARY care , *CANCER prevention , *GERIATRIC assessment , *CANCER treatment , *EPIDEMIOLOGY , *PATIENTS - Abstract
Abstract: Objective: To examine the prevalence of falls, factors associated with falls and the relationship between falls and survival in older adults with multiple myeloma. Methods: In an analysis of the Surveillance, Epidemiology and End Results (SEER)‐Medicare Health Outcomes Survey (MHOS)‐linked database, we examined 405 older adults with multiple myeloma (MM) and 513 matched non‐cancer controls. The primary outcome was self‐reported within the past 12 months. Age, race, gender, symptoms, and comorbidities were self‐reported in the MHOS. Survival was calculated from SEER data. Results: Of the patients with MM, 171 were within 1 year of diagnosis (cohort 1) and 234 were ≥1 year postdiagnosis (cohort 2). Patients in cohorts 1 and 2 were more likely to have fallen than controls (26% and 33% vs 23%,
P = .012). On multivariate analysis, among patients with myeloma (combined cohorts 1 and 2), factors associated with falls included self‐report of fatigue (aOR 2.52 [95% CI 1.34‐4.93]), depression (aOR 1.90 [95% CI 1.14‐3.18]), or poorer general health (aOR 1.86 [95% CI 1.05‐3.36]). Falls were not associated with survival. Conclusions: Older adults with MM have a greater prevalence of falls than matched controls. Self‐reported fatigue, depression, and poorer general health are associated with greater odds of falls. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
8. Racial disparities in treatment use for multiple myeloma.
- Author
-
Fiala, Mark A. and Wildes, Tanya M.
- Subjects
- *
MULTIPLE myeloma treatment , *HEALTH & race , *MEDICAL care costs , *STEM cell transplantation , *MEDICAL decision making , *ANTINEOPLASTIC agents , *STATISTICS on Black people , *REPORTING of diseases , *HEALTH services accessibility , *HEALTH status indicators , *INFORMATION retrieval , *MEDICARE , *MULTIPLE myeloma , *PROGNOSIS , *RESEARCH funding , *WHITE people , *HEALTH equity , *PROPORTIONAL hazards models - Abstract
Background: Recent treatment advances have greatly improved the prognosis of patients with multiple myeloma. However, some of these newer, more effective treatments are intensive and expensive and their use remains low, particularly among black patients.Methods: In the current study, the authors reviewed the use patterns of stem cell transplantation and bortezomib using the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database.Results: After controlling for overall health and potential access barriers, black patients were found to be 37% (P<.0001) less likely to undergo stem cell transplantation, and 21% (P<.0001) less likely to be treated with bortezomib. Moreover, the authors found that the underuse of these treatments was associated with a 12% increase in the hazard ratio for death among black patients (P = 0.0007).Conclusions: Eliminating health disparities, a current focus of US public policy, is highly complex, as illustrated by the results of the current study. In patients with multiple myeloma, treatment disparities are not completely explained by potential access barriers. Additional factors, such as structural barriers in the health care system and individual decision making among black and white patients, must be explored to fully explain the disparity. Cancer 2017;123:1590-1596. © 2017 American Cancer Society. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
9. Drug development for recurrent and refractory classical Hodgkin lymphoma.
- Author
-
Wildes, Tanya M. and Bartlett, Nancy L.
- Subjects
- *
DRUG development , *HODGKIN'S disease , *REFRACTORY materials , *CELL transplantation , *CELL surface antigens , *ANTIBODY-drug conjugates , *BISPECIFIC antibodies - Abstract
Classical Hodgkin lymphoma (cHL) is highly treatable with chemotherapy alone or combined modality therapy. High dose therapy and autologous stem cell transplant is considered standard of care for patients who relapse. For patients who relapse following transplant or who are not candidates for high dose therapy, prognosis is poor, and new treatment strategies are needed. Targeted therapies for relapsed Hodgkin lymphoma include monoclonal antibodies directed at cell surface antigens, immunoconjugates, bispecific constructs created to recruit host effector cells and radioimmunotherapy. In Epstein-Barr virus (EBV)-associated Hodgkin lymphoma, cytotoxic T lymphocytes directed at EBV antigens have been utilised in clinical trials with some success. Additionally, the immunomodulatory agents thalidomide and lenalidomide, and new classes of drugs such as the mammalian target of rapamycin inhibitors and histone deacetylase inhibitors hold promise in relapsed Hodgkin lymphoma. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
10. Dasatinib in relapsed or plateau-phase multiple myeloma.
- Author
-
Wildes, Tanya M., Procknow, Elizabeth, Gao, Feng, Dipersio, John F., and Vij, Ravi
- Subjects
- *
LETTERS to the editor , *MEDICAL research - Abstract
A letter to the editor is presented in response to the article regarding the study of Dasatinib which inhibits numerous kinases including oncogenic SRC family kinases, BCR-ABL and the PDGFβ receptor in the previous issue.
- Published
- 2009
- Full Text
- View/download PDF
11. Comorbidities, Not Age, Impact Outcomes in Autologous Stem Cell Transplant for Relapsed Non-Hodgkin Lymphoma
- Author
-
Wildes, Tanya M., Augustin, Kristan M., Sempek, Diane, Zhang, Qin Jean, Vij, Ravi, Dipersio, John F., and Devine, Steven M.
- Subjects
- *
CELLULAR therapy , *HODGKIN'S disease , *LYMPHOMAS , *TRANSPLANTATION of organs, tissues, etc. - Abstract
Abstract: High-dose chemotherapy followed by autologous peripheral blood stem cell transplantation is a widely applied treatment for advanced non-Hodgkin lymphoma (NHL), but few studies have analyzed the tolerability and outcomes in older patients compared with younger patients treated in a homogeneous manner. We retrospectively reviewed 152 consecutive patients who underwent autologous stem cell transplantation (ASCT) following BEAM conditioning (carmustine, etoposide, cytarabine, and melphalan) for NHL from January 2000 through August 2004 at our institution. We compared 59 patients age ≥60 years and 93 patients age <60 years. Supportive care was identical for all patients. The frequency of comorbidities was similar between both groups. CD34+ cell doses, days to neutrophil recovery, and days to platelet count >20,000/mm3 were similar in younger and older patients, although days to platelet count >50,000/mm3 were longer in the older patients (median 30.0 days versus 22.5 days, P = .01). Patients over the age of 60 were more likely to develop grade III/IV mucositis than their younger counterparts (37.7% versus17.4%, P = .0063). Otherwise, the frequency of other grade III/IV toxicities were similar between younger and older patients. Treatment-related mortality (TRM) was similar between older and younger patients (8.5% versus 5.4%, P = .45). Although age was not associated with TRM, the Charlson Comorbidity Index Score was significantly correlated with TRM (P = .03). Median disease-free survival was similar between older and younger patients (21.8 months versus 29.9 months, P = .93), as was overall survival (OS) (47.7 months versus 62.5 months, P = .20). After controlling for age, the Charlson Comorbidity Index Score influenced OS [P = .013]. Overall, our cohort of patients with NHL over the age of 60 who underwent ASCT following BEAM conditioning experienced toxicities and survival similar to their younger counterparts. Comorbidities significantly influenced TRM and OS in this retrospective cohort. Future study should focus on improving tolerability of conditioning and careful prospective evaluation of comorbidities and their association with outcomes. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
12. Post hoc analysis of daratumumab plus lenalidomide, bortezomib and dexamethasone in Black patients from final data of the GRIFFIN study.
- Author
-
Nooka, Ajay K., Kaufman, Jonathan L., Rodriguez, Cesar, Jakubowiak, Andrzej, Efebera, Yvonne, Reeves, Brandi, Wildes, Tanya M., Holstein, Sarah A., Anderson, Larry D., Badros, Ashraf, Shune, Leyla, Chari, Ajai, Pei, Huiling, Cortoos, Annelore, Patel, Sharmila, Lin, Thomas S., Voorhees, Peter M., Usmani, Saad Z., and Richardson, Paul G.
- Subjects
- *
BLACK people , *DARATUMUMAB , *LENALIDOMIDE , *BORTEZOMIB , *HEALTH services accessibility - Abstract
Summary: Due in part to racial disparities and underrepresentation in clinical studies, optimal therapies for Black patients with multiple myeloma remain undefined. This final analysis of GRIFFIN by race showed that the addition of daratumumab (D) to lenalidomide/bortezomib/dexamethasone (RVd) provides clinical benefit among both Black and White transplant‐eligible newly diagnosed patients compared with RVd alone. However, Black patients were more likely to discontinue ≥1 drug due to treatment‐emergent adverse events. In summary, these findings suggest a benefit of D‐RVd front‐line therapy among Black and White patients and underscore the importance of equitable treatment access for all patients. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. "They don't care to study it": Trust, race, and health care experiences among patient‐caregiver dyads with multiple myeloma.
- Author
-
Grant, Shakira J., Mills, Jiona A., Telfair, Joseph, Erisnor, Gabriell, Wildes, Tanya M., Bates‐Fraser, Lauren C., Olshan, Andrew F., Kent, Erin E., Muss, Hyman B., and Mihas, Paul
- Subjects
- *
TRUST , *MEDICAL mistrust , *MENTAL health services , *MULTIPLE myeloma , *TUSKEGEE Syphilis Study , *SERVICES for caregivers , *LIKES & dislikes - Abstract
Background: Medical mistrust, rooted in unethical research, is a barrier to cancer‐related health care for Black/African American (AA) persons. Understanding trust, mistrust, and health care experiences is crucial, especially in multiple myeloma (MM), which disproportionately burdens Black/AA persons in incidence and survival. Study Purpose: This study qualitatively examines the experiences of Black/AA and White dyads (patient with MM and adult caregiver) to gain insights into these phenomena. Methods: From November 2021 to April 2022, we recruited 21 dyads from the UNC Lineberger Comprehensive Cancer Center. Participants completed a sociodemographic survey and a 60–90 min semi‐structured interview. We used ATLAS.ti v9 for project management and to facilitate data analysis using the Sort and Sift, Think and Shift approach (ResearchTalk Inc). Results: We interviewed 21 racially concordant dyads (11 Black/AA, 10 White) with mean patient ages of 70 (Black/AA) and 72 (White) at enrollment. Both Black/AA and White caregivers had a mean enrollment age of 68. The mean duration from MM diagnosis to enrollment for all patients was 5.5 years. Four key themes emerged: (1) knowledge and trust, (2) heightened emotions and discomfort, (3) differing mental constructs of health care experiences, and (4) mitigating mistrust, which varied by self‐identified race. Black/AA participants had greater knowledge of historical events like the U.S. Public Health Service Untreated Syphilis Study at Tuskegee and carried the emotional burden longer. They also emphasized self‐learning and self‐guided research about MM for informed medical decision‐making. Both Black/AA and White dyads emphasized the pivotal role of patient‐provider relationships and effective communication in fostering trust and addressing concerns. Conclusion: Our study offers contextual insights into the enduring challenges of medical mistrust, particularly within the Black/AA community, and its implications for patients and caregivers accessing and receiving MM‐related care. Future studies should leverage these insights to guide the development of multilevel interventions addressing medical mistrust within the Black/AA community. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Geriatric Oncology: Getting Even Better with Age.
- Author
-
Klepin, Heidi D. and Wildes, Tanya M.
- Subjects
- *
GERIATRIC oncology , *GERIATRIC assessment , *SURVIVAL , *ELDER care , *CANCER patient medical care - Abstract
An introduction is presented in which the editor discusses the theme of the issue concerning geriatric oncology. Topics include geriatric assessment, the value of assessment strategies, toxicity of chemotherapy, re-hospitalization, functional decline after treatment, and survival.
- Published
- 2019
- Full Text
- View/download PDF
15. Prevalence of geriatric impairments and frailty categorization among real-world patients with multiple myeloma: a prospective cohort study (MFRAIL)
- Author
-
Haider, Imran, Leong, Darryl P., Louzada, Martha, McCurdy, Arleigh, Pond, Gregory R., Cameron, Ruthanne, Aljama, Mohammed, Visram, Alissa, Wildes, Tanya M., and Mian, Hira
- Abstract
AbstractThere is limited knowledge regarding the prevalence of geriatric impairments and frailty among patients with multiple myeloma (MM) in a real-world setting. This study evaluated the distribution of frailty profiles among 116 patients with newly diagnosed or relapsed MM, using four common frailty scales. The proportion of patients classified as frail varied significantly, ranging from 15.5% to 56.9%, due to differences in how frailty was operationalized between each frailty measure. Functional, cognitive, and mobility impairments were common overall and irrespective of performance status. Analyses between frailty and treatment selection (dose reduction and doublet vs. triplet therapy) demonstrated significant differences in non-steroid MM drug dose reductions between frail vs. non-frail patients, as scored by the International Myeloma Working Group (IMWG) Frailty Index and Simplified Frailty Score (
p < .05). A standardized approach to frailty assessment that is practical in application, and beneficial in guiding treatment selection and minimizing treatment related toxicity is necessary to provide optimal tailored care. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF
16. Falls prechemotherapy and toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer in older women: Results from the prospective multicenter HOPE trial.
- Author
-
Ji, Jingran, Bae, Marie, Sun, Can‐Lan, Wildes, Tanya M., Freedman, Rachel A., Magnuson, Allison, O'Connor, Tracey, Moy, Beverly, Klepin, Heidi D., Chapman, Andrew E., Tew, William P., Dotan, Efrat, Fenton, Mary Anne, Kim, Heeyoung, Katheria, Vani, Gross, Cary P., Cohen, Harvey J., Muss, Hyman B., and Sedrak, Mina S.
- Subjects
- *
ADJUVANT chemotherapy , *BREAST cancer , *CANCER chemotherapy , *OLDER women , *OLDER people - Abstract
Background: Older women with breast cancer frequently experience toxicity‐related hospitalizations during adjuvant chemotherapy. Although the geriatric assessment can identify those at risk, its use in clinic remains limited. One simple, low‐cost marker of vulnerability in older persons is fall history. Here, the authors examined whether falls prechemotherapy can identify older women at risk for toxicity‐related hospitalization during adjuvant chemotherapy for breast cancer. Methods: In a prospective study of women >65 years old with stage I–III breast cancer treated with adjuvant chemotherapy, the authors assessed baseline falls in the past 6 months as a categorical variable: no fall, one fall, and more than one fall. The primary end point was incident hospitalization during chemotherapy attributable to toxicity. Multivariable logistic regression was used to examine the association between falls and toxicity‐related hospitalization, adjusting for sociodemographic, disease, and geriatric covariates. Results: Of the 497 participants, 60 (12.1%) reported falling before chemotherapy, and 114 (22.9%) had one or more toxicity‐related hospitalizations. After adjusting for sociodemographic, disease, and geriatric characteristics, women who fell more than once within 6 months before chemotherapy had greater odds of being hospitalized from toxicity during chemotherapy compared to women who did not fall (50.0% vs. 20.8% experienced toxicity‐related hospitalization, odds ratio, 4.38; 95% confidence interval, 1.66–11.54, p =.003). Conclusions: In this cohort of older women with early breast cancer, women who experienced more than one fall before chemotherapy had an over 4‐fold increased risk of toxicity‐related hospitalization during chemotherapy, independent of sociodemographic, disease, and geriatric factors. In this study, nearly one in four older women with early breast cancer experienced toxicity‐related hospitalization during chemotherapy. Women who reported more than one fall in the 6 months leading up to chemotherapy had a greater than four times higher odds of experiencing toxicity‐related hospitalization during treatment than women who reported no falls. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
17. Frailty in Older Adults With Multiple Myeloma: A Study of US Veterans.
- Author
-
Patel, Bindiya G., Luo, Suhong, Wildes, Tanya M., and Sanfilippo, Kristen M.
- Subjects
- *
MULTIPLE myeloma , *OLDER people , *VETERANS , *ELECTRONIC health records , *CONFOUNDING variables , *ECONOMIC expectations , *BODY mass index - Abstract
PURPOSE: Age-associated cumulative decline across physiologic systems results in a diminished resistance to stressors, including cancer and its treatment, creating a vulnerable state known as frailty. Frailty is associated with increased risk of adverse outcomes in patients with cancer. Identification of frailty in administrative data can allow for assessment of prognosis and facilitate control for confounding variables. The purpose of this study was to assess frailty from claims-based data using the accumulation of deficits approach in veterans with multiple myeloma (MM). METHODS: From the Veterans Administration Central Cancer Registry, we identified patients who were diagnosed with MM between 1999 and 2014. Using the accumulation of deficits approach, we calculated a Frailty Index (FI) using 31 health-associated deficits and categorized scores into five groups: nonfrail (FI, 0 to 0.1), prefrail (FI, 0.11 to 0.20), mild frailty (FI, 0.21 to 0.30), moderate frailty (FI, 0.31 to 0.40), and severe frailty (FI, > 0.4). We used Cox proportional hazards regression analysis to assess association between FI score and mortality while adjusting for potential confounders. RESULTS: We calculated an FI for 3,807 veterans age 65 years or older. Among the cohort, 28.7% were classified as nonfrail, 41.3% prefrail, 21.6% mildly frail, 6.6% moderately frail, and 1.7% severely frail. Frailty was strongly associated with mortality independent of age, race, MM treatment, body mass index, or statin use. Higher FI score was associated with higher mortality with hazard ratios of 1.33 (95% CI, 1.21 to 1.47), 1.97 (95% CI, 1.70 to 2.20), 2.86 (95% CI, 2.45 to 3.34), and 3.22 (95% CI, 2.46 to 4.22) for prefrail, mildly frail, moderately frail, and severely frail, respectively. CONCLUSION: Frailty status is a significant predictor of mortality in older veterans with MM. Assessment of frailty status using the readily available electronic medical records data in administrative data allows for assessment of prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. "A lot to manage and still have some kind of a life": How multiple myeloma impacts the function and quality‐of‐life of Black–White patient–caregiver dyads.
- Author
-
Bates‐Fraser, Lauren C., Mills, Jiona, Mihas, Paul, Wildes, Tanya M., Kent, Erin E., Erisnor, Gabriell, Adams, Leah, and Grant, Shakira J.
- Subjects
- *
CAREGIVER attitudes , *CANCER patient psychology , *SOCIAL support , *HEALTH services accessibility , *FUNCTIONAL status , *RESEARCH methodology , *ATTITUDE (Psychology) , *INTERVIEWING , *BURDEN of care , *ACQUISITION of data , *PATIENTS' attitudes , *QUALITATIVE research , *LIFE , *SURVEYS , *EXPERIENCE , *QUALITY of life , *RESEARCH funding , *PSYCHOLOGY of caregivers , *QUESTIONNAIRES , *SOUND recordings , *MEDICAL records , *MULTIPLE myeloma , *WHITE people , *THEMATIC analysis , *DATA analysis software , *PSYCHOLOGICAL adaptation , *AFRICAN Americans - Abstract
Background: Multiple myeloma (MM) is an incurable debilitating blood cancer associated with the lowest health related quality of life (HRQoL) of all cancers. With nearly 88% of adults aged ≥55 years at diagnosis, age‐associated physical losses, comorbidities, and social factors contribute to worsening HRQoL. This qualitative study assessed dyadic (patient–informal caregiver) perspectives on the factors contributing to HRQoL in MM survivors. Methods: We recruited 21 dyads from the UNC‐Chapel Hill Lineberger Comprehensive Cancer between 11/2021 and 04/2022. Participants completed a single dyadic semistructured interview capturing broad perspectives on MM. We used ATLAS. ti v 9 for project management and to facilitate data analysis using the Sort and Sift, Think and Shift approach (ResearchTalk, Inc.). This iterative approach allowed the exploration and identification of themes within and across transcripts. Results: The mean age at enrollment was 71 years (median: 71, range: 57–90) for patients and 68 years (median 67, range: 37–88) for caregivers. All dyads were racially concordant (11 Black/AA and 10 White). However, we aggregated the findings due to no consistent racial differences. Six themes related to (1) physical burden, (2) treatment challenges, (3) losses of independence, (4) caregiver burden, (5) patient and caregiver perseverance, and (6) adjustment to a new normal were identified. Dyads also experienced MM together, resulting in patients and caregivers experiencing changes in their ability to engage in physical and social activities, which further contributed to poor HRQoL. Patients' increased need for social support led to shifts in the caregiver roles, resulting in caregivers feeling burdened by their responsibilities. All dyads acknowledged the need for perseverance and adaptability to a new normal with MM. Conclusion: The functional, psychosocial, and HRQoL of older patients with MM and their caregivers remain impacted ≥6 months after a new diagnosis highlighting clinical and research opportunities to focus on preserving or improving the health of dyads living with MM. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
19. Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma.
- Author
-
Michel, Loren, Ley, Jessica, Wildes, Tanya M., Schaffer, András, Robinson, Anthony, Chun, Se-Eun, Lee, Wooin, Jr.Lewis, James, Trinkaus, Kathryn, Adkins, Douglas, and Lewis, James Jr
- Subjects
- *
CETUXIMAB , *SQUAMOUS cell carcinoma , *MYELOSUPPRESSION , *PHARMACOKINETICS , *PROTEIN expression , *TUMORS , *THERAPEUTICS , *HETEROCYCLIC compounds , *PYRIDINE , *CANCER relapse , *CLINICAL trials , *HEAD tumors , *NECK tumors , *TRANSFERASES - Abstract
Objectives: To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma (HNSCC).Materials and Methods: A phase I trial using 3+3 design was performed to determine the dose limiting toxicity (DLT) and maximum tolerated dose (MTD) of palbociclib with standard dose weekly cetuximab. Palbociclib was administered orally days 1-21 every 28days: dose level 1 (100mg/d) and 2 (125mg/d; approved monotherapy dose). Pharmacokinetic assessments were performed on cycle 2, day 15. Cyclin D1, p16(INK4a), and Rb protein expression were measured on pre-treatment tumor. Tumor response was assessed using RECIST1.1.Results: Nine patients (five p16(INK4a) negative; four positive) were enrolled across dose levels 1 (n=3) and 2 (n=6) and none experienced a DLT. A MTD of palbociclib was not reached. Myelosuppression was the most common adverse event. Six of nine patients had cetuximab-resistant and 4/9 had platin-resistant disease. Disease control (DC) occurred in 89%, including partial response (PR) in two (22%) and stable disease in six (67%) patients. PRs occurred in p16(INK4a) negative HNSCC. Five patients (56%) had measurable decreases in tumor target lesions. In cetuximab-resistant HNSCC, best tumor response was PR in 1 and DC in 5 and median TTP was 112days (range: 28-168). In platin-resistant HNSCC, best tumor response: PR in 1, DC in 3 and median TTP was 112days (range: 28-112). The Cmax and AUC0-24h appeared comparable in patients receiving 125 vs 100mg dose of palbociclib.Conclusion: This trial, the first to evaluate a CDK4/6 inhibitor in HNSCC, determined that palbociclib 125mg/day on days 1-21 every 28days with cetuximab was safe. Tumor responses were observed, even in cetuximab- or platin-resistant disease. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
20. Cisplatin versus Cetuximab Given Concurrently with Definitive Radiation Therapy for Locally Advanced Head and Neck Squamous Cell Carcinoma.
- Author
-
Ley, Jessica, Mehan, Paul, Wildes, Tanya M., Thorstad, Wade, Gay, Hiram A., Michel, Loren, Nussenbaum, Brian, Trinkaus, Kathryn, and Adkins, Douglas
- Subjects
- *
CISPLATIN , *THERAPEUTIC use of monoclonal antibodies , *HEAD tumors , *NECK tumors , *ACADEMIC medical centers , *COMBINED modality therapy , *COMPARATIVE studies , *CONFIDENCE intervals , *DIAGNOSTIC imaging , *FISHER exact test , *MEDICAL records , *RADIOTHERAPY , *RESEARCH funding , *STATISTICS , *T-test (Statistics) , *DATA analysis , *PROPORTIONAL hazards models , *RETROSPECTIVE studies , *DATA analysis software , *DESCRIPTIVE statistics , *TUMOR treatment - Abstract
Objective: Whether or not cisplatin and cetuximab are similarly effective in improving outcomes when added to radiation therapy (RT) in squamous cell carcinoma of the head and neck is unknown. Methods: Retrospective analysis was performed of patients treated with definitive RT and cisplatin (n = 18) or cetuximab (n = 29). Results: T and N classifications, stage, human papillomavirus status and smoking history were balanced in the two groups; however, patients in the cisplatin group were younger and had a better performance status. Delivery of RT was similar between the two groups. Median follow-up was 23 (4-64) months. Disease-specific survival (DSS) at 3 years was 83% in the cisplatin group and 31% in the cetuximab group. Recurrent disease was more common in the cetuximab group compared with the cisplatin group (17 vs. 4 patients). Propensity score analysis to adjust for differences in patient characteristics which influenced treatment selection showed that DSS was indeed longer with cisplatin than with cetuximab (DSS hazard ratio 0.15, confidence interval 0.033, 0.66; p = 0.012). Conclusions: DSS was superior in the patients given cisplatin with definitive RT compared to cetuximab with definitive RT due to a lower risk of recurrent disease in the cisplatin group. These observations could not be explained by differences between the two groups in the patient and tumor characteristics or in treatment delivery. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
21. A single center retrospective study of daratumumab, pomalidomide, and dexamethasone as 2nd-line therapy in multiple myeloma.
- Author
-
Liu, Lawrence, Fiala, Mark, Gao, Feng, King, Justin, Goldsmith, Scott, Wildes, Tanya M., Stockerl-Goldstein, Keith, Vij, Ravi, and Schroeder, Mark A.
- Subjects
- *
DARATUMUMAB , *MULTIPLE myeloma , *PROGRESSION-free survival , *DEXAMETHASONE , *CYTOGENETICS - Abstract
Daratumumab, pomalidomide, and dexamethasone (DPd) is an FDA-approved 3rd or later line of therapy for myeloma. However, as there are limited published data on the efficacy of 2nd-line DPd, we conducted a retrospective analysis (n = 33). Herein, we report our center's data for 2nd-line DPd. Our patient population had a high amount of high risk cytogenetics (45.5%). The overall response rate (ORR) was 84.9% with a 1-year Progression Free Survival (PFS) of 37.7%. In standard risk myeloma (n = 18), the ORR was 88.9% and 1-year PFS was 61.1% (95% CI 42.3–88.3%). In high risk myeloma (45.5%, n = 15), the ORR was 80% with a 1-year PFS of 7.3% (95% CI 1.1–47.9%). This suggests that the efficacy of 2nd-line DPd in myeloma with high risk cytogenetics should be further investigated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. A 54-Year-Old Man With a Rash and Pulmonary lnfiltrates.
- Author
-
Lawrence, Kevin, Hachem, Ramsey, Wildes, Tanya M., and Canizares, Maria
- Subjects
- *
SKIN diseases , *LUNG diseases , *PULMONARY alveoli , *ADRENOCORTICAL hormones , *ETIOLOGY of diseases , *DISEASES - Abstract
The article reports a case of sweet syndrome or acute febrile neutrophilic dermatoses in a 54-year-old man. A probable etiology of pulmonary infiltrates was sweet syndrome with lung involvement or neutrophilic alveolitis. The patient was treated with systemic corticosteroids and experienced a fast resolution of the rash and pulmonary infiltrates. The patient also underwent a bone marrow biopsy, and the findings were consistent with a myelodysplastic syndrome.
- Published
- 2008
- Full Text
- View/download PDF
23. A deficit-accumulation frailty index predicts survival outcomes in patients with gynecologic malignancy.
- Author
-
Mullen, Mary M., McKinnish, Tyler R., Fiala, Mark A., Zamorano, Abigail S., Kuroki, Lindsay M., Fuh, Katherine C., Hagemann, Andrea R., McCourt, Carolyn K., Mutch, David G., Powell, Matthew A., Wildes, Tanya M., and Thaker, Premal H.
- Subjects
- *
SURVIVAL rate , *OVERALL survival , *VULVAR cancer , *GYNECOLOGIC cancer , *CANCER-related mortality , *AGE , *WOMEN'S mortality - Abstract
To determine the association between scores from a 25-item patient-reported Rockwood Accumulation of Deficits Frailty Index (DAFI) and survival outcomes in gynecologic cancer patients. A frailty index was constructed from the SEER-MHOS database. The DAFI was applied to women age ≥ 65 diagnosed with all types of gynecologic cancers between 1998 and 2015. The impact of frailty status at cancer diagnosis on overall survival (OS) was analyzed using Kaplan-Meier curves and Cox proportional hazards regression. In this cohort (n = 1336) the median age at diagnosis was 74 (range 65–97). Nine hundred sixty-two (72%) women were Caucasian and 132 (10%) were African-American. Overall, 651(49%) of patients were considered frail. On multivariate analysis, frail patients had a 48% increased risk for death (aHR 1.48; 95% CI 1.29–1.69; P < 0.0001). Each 10% increase in frailty index was associated with a 16% increased risk of death (aHR, 1.16; 95% CI, 1.11 to 1.21; P < 0.0001). In subgroup analyses of the varying cancer types, the association of frailty status with prognosis was fairly consistent (aHR 1.15–2.24). The DAFI was more prognostic in endometrial (aHR 1.76; 95% CI 1.41–2.18, P < 0.0001) and vaginal/vulvar (aHR 1.94; 95% CI 1.34–2.81, P = 0.0005) cancers as well as patients with loco-regional disease (aHR 1.94; 95% CI 1.62–2.33, P < 0.0001). Frailty appears to be a significant predictor of mortality in gynecologic cancer patients regardless of chronological age. This measure of functional age may be of particular utility in women with loco-regional disease only who otherwise would have a favorable prognosis. • Frailty is a significant predictor of mortality in women with gynecologic malignancies. • Frailty score is directly associated with risk of death in this patient population. • Frailty is high prognostic in women with endometrial and vaginal/vulvar cancers and those with loco-regional disease only. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
24. Renal failure among multiple myeloma patients utilizing carfilzomib and associated factors in the "real world".
- Author
-
Mian, Hira S., Fiala, Mark A., Sanchez, Larysa, Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
KIDNEY failure , *MULTIPLE myeloma , *CHRONIC kidney failure , *NOSOLOGY , *MONOCLONAL gammopathies , *PROTEASOME inhibitors , *HEART failure - Abstract
Carfilzomib, a next-generation proteasome inhibitor, improves outcomes in patients with multiple myeloma (MM); however, a proportion of those treated develop renal failure due to adverse event, comorbidity, or myeloma progression. The rate of renal failure and associated risk factors remains unknown in real-world populations. Adults with relapsed/refractory MM who received carfilzomib between the years 2013 and 2016 were identified in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked databases. Renal failure was defined using the corresponding International Classification of Diseases, Ninth Revision (ICD-9) and Tenth Revision (ICD-10) diagnostic codes and procedure codes for dialysis. Patients with a pre-existing diagnosis of renal failure were excluded to distinguish an adverse event from comorbidity. Multivariate cox regression analysis was performed to identify the variables independently associated with the development of renal failure among MM patients utilizing carfilzomib. A total of 1950 patients were included in the analysis. Renal failure developed in 22% of patients during the study period. The median time to development of renal failure from first carfilzomib administration was 1.6 months (range < 0.1–23.3). Increasing age (adjusted hazard ratio [aHR] 1.01 per year, p = 0.018), pre-existing heart failure (aHR 1.50, p = 0.005), and pre-existing chronic kidney disease (aHR 2.00, p < 0.001) were associated with a higher risk of developing renal failure. Renal failure occurred in up to 22% of patients on carfilzomib therapy. The exact cause and mechanism of renal failure cannot be determined from our study and may be multifactorial. Future studies are needed to further understand the cause of renal failure among patients on carfilzomib and devise strategies to mitigate the risk. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
25. Treatment decision-making in acute myeloid leukemia: a qualitative study of older adults and community oncologists.
- Author
-
Loh, Kah Poh, Abdallah, Maya, Kadambi, Sindhuja, Wells, Megan, Kumar, Anita J., Mendler, Jason H., Liesveld, Jane L., Wittink, Marsha, O'Dwyer, Kristen, Becker, Michael W., McHugh, Colin, Stock, Wendy, Majhail, Navneet S., Wildes, Tanya M., Duberstein, Paul, Mohile, Supriya Gupta, and Klepin, Heidi D.
- Subjects
- *
ACUTE myeloid leukemia , *OLDER people , *ONCOLOGISTS , *OLDER patients , *DECISION making - Abstract
Little is known about the characteristics of patients, physicians, and organizations that influence treatment decisions in older patients with AML. We conducted qualitative interviews with community oncologists and older patients with AML to elicit factors that influence their treatment decision-making. Recruitment was done via purposive sampling and continued until theoretical saturation was reached, resulting in the inclusion of 15 patients and 15 oncologists. Participants' responses were analyzed using directed content analysis. Oncologists and patients considered comorbidities, functional status, emotional health, cognition, and social factors when deciding treatment; most oncologists evaluated these using clinical gestalt. Sixty-seven percent of patients perceived that treatment was their only option and that they had not been offered a choice. In conclusion, treatment decision-making is complex and influenced by patient-related factors. These factors can be assessed as part of a geriatric assessment which can help oncologists better determine fitness and guide treatment decision-making. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
26. Barriers to Hematopoietic Cell Transplantation for Adults in the United States: A Systematic Review with a Focus on Age.
- Author
-
Flannelly, Colin, Tan, Bryan E-Xin, Tan, Jian Liang, McHugh, Colin M., Sanapala, Chandrika, Lagu, Tara, Liesveld, Jane L., Aljitawi, Omar, Becker, Michael W., Mendler, Jason H., Klepin, Heidi D., Stock, Wendy, Wildes, Tanya M., Artz, Andrew, Majhail, Navneet S., and Loh, Kah Poh
- Subjects
- *
CELL transplantation , *NURSING databases , *OLDER patients , *HEMATOLOGIC malignancies , *GERIATRIC assessment , *ADULTS - Abstract
• There are significant barriers to accessing hematopoietic cell transplantation (HCT). • High-quality studies are lacking related to HCT barriers. • Older age and nonwhite race were consistently linked to reduced access to HCT. • Strategies to overcome these barriers for these vulnerable populations should be prioritized. Hematopoietic cell transplantation (HCT) is an effective treatment for many hematologic malignancies, and its utilization continues to rise. However, due to the difficult logistics and high cost of HCT, there are significant barriers to accessing the procedure; these barriers are likely greater for older patients. Although numerous factors may influence HCT access, no formal analysis has detailed the cumulative barriers that have been studied thus far. We conducted a systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines to better categorize the barriers to access and referral to HCT, with a focus on the subgroup of older patients. We searched for articles published in English from PubMed, Embase, Cumulative Index for Nursing and Allied Health, and Cochrane Central Register of Controlled Trials between the database inception and January 31, 2020. We selected articles that met the following inclusion criteria: (1) study design: qualitative, cross-sectional, observational cohort, or mixed-method study designs; (2) outcomes: barriers related to patient and physician access to HCT; and (3) population: adults aged ≥18 years with hematologic malignancies within the United States. Abstracts without full text were excluded. QUALSYST methodology was used to determine article quality. Data on the barriers to access and referral for HCT were extracted, along with other study characteristics. We summarized the findings using descriptive statistics. We included 26 of 3859 studies screened for inclusion criteria. Twenty studies were retrospective cohorts and 4 were cross-sectional. There was 1 prospective cohort study and 1 mixed-method study. Only 1 study was rated as high quality, and 16 were rated as fair. Seventeen studies analyzed age as a potential barrier to HCT referral and access, with 16 finding older age to be a barrier. Other consistent barriers to HCT referral and access included nonwhite race (n = 16/20 studies), insurance status (n = 13/14 studies), comorbidities (n = 10/11 studies), and lower socioeconomic status (n = 7/8 studies). High-quality studies are lacking related to HCT barriers. Older age and nonwhite race were consistently linked to reduced access to HCT. To produce a more just health care system, strategies to overcome these barriers for vulnerable populations should be prioritized. Examples include patient and physician education, as well as geriatric assessment guided care models that can be readily incorporated into clinical practice. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
27. DCEP and bendamustine/prednisone as salvage therapy for quad- and penta-refractory multiple myeloma.
- Author
-
Goldsmith, Scott R., Fiala, Mark A., Wang, Brandon, Schroeder, Mark A., Wildes, Tanya M., Ghobadi, Armin, Stockerl-Goldstein, Keith, and Vij, Ravi
- Subjects
- *
MULTIPLE myeloma , *SALVAGE therapy , *PROGRESSION-free survival , *LONGITUDINAL method , *ETOPOSIDE , *PREDNISOLONE , *DEXAMETHASONE , *ANTINEOPLASTIC agents , *RETROSPECTIVE studies , *PROGNOSIS , *CYCLOPHOSPHAMIDE , *CISPLATIN - Abstract
Multiple myeloma (MM) almost invariably progresses through novel therapies. Patients with quad-refractory MM (refractory to bortezomib, carfilzomib, lenalidomide, and pomalidomide) and penta-refractory MM (additional refractoriness to daratumumab) have few treatment options. Two chemotherapy regimens, bendamustine/prednisone (BP) and dexamethasone, cyclophosphamide, etoposide, and cisplatin (DCEP), are often used in quad- and penta-refractory MM, but there are limited data on outcomes in this heavily pre-treated population. We conducted a single-center retrospective study to identify all patients who received DCEP and/or BP for quad- or penta-refractory MM. Disease response and refractoriness were defined by International Myeloma Working Group criteria. The primary endpoint was overall response rate (ORR). Secondary endpoints included overall survival (OS), progression-free survival (PFS), and duration of response (DOR). We identified 27 patients who received BP for quad- or penta-refractory MM. The median number of prior lines of therapy was 6. The ORR for BP was 26%. The median PFS for BP was 1.4 months (95% CI 1.1-1.6) and median OS was 8.7 months (95% CI 2.3-15.0). Patients treated with cyclophosphamide had less response to BP. Thirty-one patients received DCEP for quad-refractory or penta-refractory MM. The median number of prior treatment regimens was 8. The ORR to DCEP was 35%. The median PFS was 2.7 months (95% CI 1.5-3.8) and median OS was 6.2 months (95% CI 4.4-7.8). DCEP and BP retain efficacy in quad- and penta-refractory MM. Our analysis supports prospective study of these regimens, possibly in combination or in comparison with other agents in this area of unmet need. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
28. Measuring cardiopulmonary complications of carfilzomib treatment and associated risk factors using the SEER-Medicare database.
- Author
-
Fakhri, Bita, Fiala, Mark A., Shah, Nina, Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
OBSTRUCTIVE lung diseases , *THERAPEUTIC complications , *OLDER people , *RESPIRATORY infections - Abstract
Background: Carfilzomib improves survival in patients with recurrent myeloma. Given the strict eligibility criteria in clinical trials, the actual frequency of cardiac adverse events (CAEs) and pulmonary adverse events (PAEs) and the risk factors associated with these AEs in the general population need to be established.Methods: The authors extracted myeloma cases in the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database from 2000 through 2013 and corresponding claims through 2014. They then identified patients who received carfilzomib during their disease course. Subsequently, the International Classification of Diseases, Ninth Revision (ICD-9) was used to identify all the codes for CAEs, PAEs, and respiratory infections associated with carfilzomib use. Preexisting diagnoses corresponding to the CAEs and PAEs of interest were excluded to distinguish toxicity from comorbidity. Multivariate Cox regression was performed to determine those variables independently associated with the development of CAEs and PAEs.Results: Of the 635 patients analyzed, the median age was 72 years (range, 36-94 years); 55% of the patients were male and 79% were white. The median duration of carfilzomib treatment was 58 days (range, 1-716 days). Overall, approximately 66% of the patients had codes for either CAEs or PAEs. In terms of CAEs, approximately 22% of patients developed hypertension, 15% developed peripheral edema, and 14% experienced heart failure. With regard to PAEs, approximately 28% of patients developed dyspnea, 15% developed cough, and 15% developed pneumonia. Only chronic obstructive pulmonary disease (COPD) was found to be independently associated with the development of CAEs. Patients with preexisting COPD were found to have a 40% increase in their hazard of developing CAEs (adjusted hazard ratio, 1.40; 95% CI, 1.03-1.90).Conclusions: In older adults with myeloma who are undergoing treatment with carfilzomib, new cardiac and pulmonary diagnoses were common. Patients with preexisting COPD were found to be at an increased risk of developing CAEs. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
29. An Analysis of the Inclusion of Medications Considered Potentially Inappropriate in Older Adults in Chemotherapy Templates for Hematologic Malignancies: One Recommendation for All?
- Author
-
Zhou, Amy, Holmes, Holly M., Hurria, Arti, and Wildes, Tanya M.
- Subjects
- *
CANCER chemotherapy , *RESEARCH funding , *STATISTICS , *DATA analysis , *DATA analysis software , *DESCRIPTIVE statistics , *HEMATOLOGIC malignancies , *IN vitro studies , *INAPPROPRIATE prescribing (Medicine) , *OLD age - Abstract
Background: There remains a paucity of data regarding the use of potentially inappropriate medications (PIMs) in the supportive management of older adults undergoing chemotherapy. Raising awareness among healthcare providers regarding the frequency of their use and potential toxicities may help to minimize the risks to patients.Objective: The aim of this study was to evaluate the frequency of six specific classes of medications considered PIMs by the American Geriatrics Society Beers Criteria that are commonly included in the National Comprehensive Cancer Network (NCCN) chemotherapy order templates for hematologic malignancies. The six PIMs evaluated are first-generation antihistamines, benzodiazepines, corticosteroids, H2-receptor antagonists, metoclopramide, and antipsychotics.Methods: A total of 311 unique chemotherapy order templates published online by the NCCN for the treatment of hematologic malignancies were reviewed to determine the frequency that these six specific PIMs were recommended for supportive care.Results: Approximately 45% of the NCCN chemotherapy templates for hematologic malignancies specifically recommended the use of at least one of the six PIMs examined. The remainder of the templates evaluated referred exclusively to the NCCN Guidelines® on Oncology for Antiemesis, which also included the use of at least one of the six PIMs evaluated.Conclusions: These findings demonstrate that PIMs are frequently used as supportive therapy in the treatment of hematologic malignancies. Increasing healthcare provider awareness of their potential side effects may minimize the risks associated with their use in older adults with hematologic malignancies undergoing chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
30. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets.
- Author
-
Fiala, Mark A., Dukeman, James, Tuchman, Sascha A., Keller, Matt, Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
MULTIPLE myeloma treatment , *SURVIVAL analysis (Biometry) , *MEDICAL databases , *MEDICARE , *HYPERCALCEMIA - Abstract
Purpose The distinction of patients with symptomatic multiple myeloma (MM) from those with smoldering MM poses a challenge for researchers who use administrative databases. Historically, researchers either have included all patients or used treatment receipt as the distinguishing factor; both methods have drawbacks. We present an algorithm for distinguishing between symptomatic and smoldering MM using ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes for the classic defining events of symptomatic MM commonly referred to as the CRAB criteria (hypercalcemia, renal impairment, anemia, and bone lesions). Patients and Methods SEER-Medicare-linked data from 4,187 patients with MM diagnosed between 2007 and 2011 were used for this analysis. Results Eighty-four percent had ICD-9-CM codes consistent with CRAB criteria, whereas only 57% received treatment. Overall survival of patients with symptomatic MM defined as receipt of treatment was 32.3 months versus 26.6 months for the overall population and 22.9 months for patients with symptomatic MM defined by CRAB criteria. Conceptually, removal of patients with smoldering MM should result in a reduction in overall survival; however, the cohort of patients who received treatment tended to be younger and healthier than the overall population, which could have skewed the results. Conclusion The algorithm we present resulted in a larger and more representative sample than classification by treatment status and reduced potential bias that could result from including all patients with smoldering MM in the analysis. Although this study was performed using the SEER-Medicare database, the methodology was broad enough that the algorithm could be extended to additional claims-based data sets with relative ease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
31. nab-Paclitaxel-based induction chemotherapy with or without cetuximab for locally advanced head and neck squamous cell carcinoma.
- Author
-
Adkins, Douglas, Ley, Jessica, Oppelt, Peter, Wildes, Tanya M., Gay, Hiram A., Daly, Mackenzie, Rich, Jason, Paniello, Randal C., Jackson, Ryan, Pipkorn, Patrik, Nussenbaum, Brian, Trinkaus, Kathryn, and Thorstad, Wade
- Subjects
- *
SQUAMOUS cell carcinoma , *CANCER treatment , *CANCER chemotherapy , *PACLITAXEL , *CETUXIMAB , *DISEASE incidence , *THERAPEUTICS - Abstract
Objectives: To explore the effect of incorporating cetuximab into induction chemotherapy in locally advanced head and neck squamous cell carcinoma (HNSCC).Materials and Methods: Retrospective comparative analysis of two consecutive prospective phase II trials was performed: trial 1 with nab-paclitaxel/cisplatin/5-FU and cetuximab (APF-C; n=30) and trial 2 with APF (n=30). Patients were scheduled to receive chemoradiation therapy (CRT) with cisplatin. T2-4 classification oropharynx (OP)/larynx/hypopharynx SCC were included. Cumulative incidence of death of disease (CIDD), overall survival (OS), and cumulative incidence of relapse were compared between APF-C and APF.Results: No significant differences in patient or tumor characteristics were noted between the groups. Median follow-up of surviving patients was 52 (25-95) months. Relapse occurred in 5 (17%) patients treated with APF-C and in 2 (7%) treated with APF (p=0.37). In human papillomavirus (HPV)-related OPSCC (n=34), the CIDD at 52months was 3.4% with APF-C and 2.6% with APF and the two-year OSs were 94%. In HPV-unrelated HNSCC (n=25), the CIDD at 52months was 4.4% with APF-C and 3.3% with APF and two-year OSs were 83% and 92%, respectively. CIDD or OS did not differ when stratified by treatment group and HPV status (CIDD: p=0.80; OS: p=0.30).Conclusion: This exploratory retrospective comparative analysis demonstrated no significant difference in CIDD, OS, or cumulative incidence of relapse between patients treated with APF-C or APF. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
32. Development of an Algorithm to Distinguish Smoldering Versus Symptomatic Multiple Myeloma in Claims-Based Data Sets.
- Author
-
Fiala, Mark A., Dukeman, James, Tuchman, Sascha A., Keller, Matt, Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
MULTIPLE myeloma , *NOSOLOGY , *CLASSIFICATION algorithms , *MEDICAL databases , *ALGORITHMS , *SHELLFISH fisheries ,INTERNATIONAL Statistical Classification of Diseases & Related Health Problems - Abstract
Purpose: The distinction of patients with symptomatic multiple myeloma (MM) from those with smoldering MM poses a challenge for researchers who use administrative databases. Historically, researchers either have included all patients or used treatment receipt as the distinguishing factor; both methods have drawbacks. We present an algorithm for distinguishing between symptomatic and smoldering MM using ICD-9-CM (International Classification of Diseases, Ninth Revision, Clinical Modification) codes for the classic defining events of symptomatic MM commonly referred to as the CRAB criteria (hypercalcemia, renal impairment, anemia, and bone lesions). Patients and Methods: SEER-Medicare–linked data from 4,187 patients with MM diagnosed between 2007 and 2011 were used for this analysis. Results: Eighty-four percent had ICD-9-CM codes consistent with CRAB criteria, whereas only 57% received treatment. Overall survival of patients with symptomatic MM defined as receipt of treatment was 32.3 months versus 26.6 months for the overall population and 22.9 months for patients with symptomatic MM defined by CRAB criteria. Conceptually, removal of patients with smoldering MM should result in a reduction in overall survival; however, the cohort of patients who received treatment tended to be younger and healthier than the overall population, which could have skewed the results. Conclusion: The algorithm we present resulted in a larger and more representative sample than classification by treatment status and reduced potential bias that could result from including all patients with smoldering MM in the analysis. Although this study was performed using the SEER-Medicare database, the methodology was broad enough that the algorithm could be extended to additional claims-based data sets with relative ease. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
33. Geriatric assessment factors are associated with mortality after hospitalization in older adults with cancer.
- Author
-
Jonna, Sushma, Chiang, Leslie, Liu, Jingxia, Carroll, Maria, Flood, Kellie, Wildes, Tanya, Carroll, Maria B, and Wildes, Tanya M
- Subjects
- *
GERIATRIC assessment , *HOSPITAL care , *CANCER-related mortality , *CANCER treatment , *LONGITUDINAL method , *PROGNOSIS , *RESEARCH funding , *SURVIVAL , *TUMORS , *RETROSPECTIVE studies ,AGE factors in cancer - Abstract
Purpose: Survival in older adults with cancer varies given differences in functional status, comorbidities, and nutrition. Prediction of factors associated with mortality, especially in hospitalized patients, allows physicians to better inform their patients about prognosis during treatment decisions. Our objective was to analyze factors associated with survival in older adults with cancer following hospitalization.Methods: Through a retrospective cohort study, we reviewed 803 patients who were admitted to Barnes-Jewish Hospital's Oncology Acute Care of Elders (OACE) unit from 2000 to 2008. Data collected included geriatric assessments from OACE screening questionnaires as well as demographic and medical history data from chart review. The primary end point was time from index admission to death. The Cox proportional hazard modeling was performed.Results: The median age was 72.5 years old. Geriatric syndromes and functional impairment were common. Half of the patients (50.4 %) were dependent in one or more activities of daily living (ADLs), and 74 % were dependent in at least one instrumental activity of daily living (IADLs). On multivariate analysis, the following factors were significantly associated with worse overall survival: male gender; a total score <20 on Lawton's IADL assessment; reason for admission being cardiac, pulmonary, neurologic, inadequate pain control, or failure to thrive; cancer type being thoracic, hepatobiliary, or genitourinary; readmission within 30 days; receiving cancer treatment with palliative rather than curative intent; cognitive impairment; and discharge with hospice services.Conclusions: In older adults with cancer, certain geriatric parameters are associated with shorter survival after hospitalization. Assessment of functional status, necessity for readmission, and cognitive impairment may provide prognostic information so that oncologists and their patients make more informed, individualized decisions. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
34. nab-Paclitaxel, cisplatin, and 5-fluorouracil followed by concurrent cisplatin and radiation for head and neck squamous cell carcinoma.
- Author
-
Adkins, Douglas, Ley, Jessica, Michel, Loren, Wildes, Tanya M., Thorstad, Wade, Gay, Hiram A., Daly, Mackenzie, Rich, Jason, Paniello, Randal, Uppaluri, Ravindra, Jackson, Ryan, Trinkaus, Kathryn, and Nussenbaum, Brian
- Subjects
- *
HEAD & neck cancer treatment , *PACLITAXEL , *CISPLATIN , *CANCER radiotherapy , *SQUAMOUS cell carcinoma , *CANCER relapse , *ANTINEOPLASTIC agents , *CANCER treatment , *CLINICAL trials , *COMPARATIVE studies , *FLUOROURACIL , *HEAD tumors , *RESEARCH methodology , *NECK tumors , *RESEARCH funding , *EVALUATION research , *TUMOR treatment - Abstract
Objectives: We previously reported the efficacy of nab-paclitaxel added to cisplatin, 5-FU, and cetuximab (APF-C) followed by concurrent high dose bolus cisplatin and radiation therapy (CRT) in patients with locally advanced head and neck squamous cell carcinoma (HNSCC). In this phase II trial, we determined the efficacy of APF (without cetuximab) followed by CRT in similar patients.Materials and Methods: Eligible patients had stage III-IV oropharynx (OP), larynx, or hypopharynx SCC and adequate organ function and performance status. T1 tumors were excluded. Patients were treated with three cycles of APF followed by CRT. Efficacy endpoints included two-year disease-specific survival (DSS), progression-free survival (PFS), overall survival (OS), and relapse rate.Results: Thirty patients were enrolled. Most patients were smokers (77%) with bulky T3/4 (73%) and N2/3 (83%) tumors. Analyses were stratified for human papilloma virus (HPV) status: HPV-related OPSCC (n=17; 57%) and HPV-unrelated HNSCC (n=13; 43%). With a minimum follow-up of 21months, relapse occurred in 1 (3%) patient. Two-year DSS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year PFS was 94% in HPV-related OPSCC and 100% in HPV-unrelated HNSCC. Two-year OS was 94% in HPV-related OPSCC and 92% in HPV-unrelated HNSCC. Causes of death were relapse (1), treatment-related mortality (1), and co-morbidity (1). Two patients with HPV-unrelated HNSCC treated with APF declined CRT and remained free of relapse at 36 and 28months of follow-up.Conclusion: This phase II trial demonstrated favorable two-year DSS, PFS, and OS and a low relapse rate in HPV-unrelated HNSCC and HPV-related OPSCC treated with APF followed by CRT. [ABSTRACT FROM AUTHOR]- Published
- 2016
- Full Text
- View/download PDF
35. Effect of Intensive Chemotherapy on Physical, Cognitive, and Emotional Health of Older Adults with Acute Myeloid Leukemia.
- Author
-
Klepin, Heidi D., Tooze, Janet A., Pardee, Timothy S., Ellis, Leslie R., Berenzon, Dmitriy, Mihalko, Shannon L., Danhauer, Suzanne C., Rao, Arati V., Wildes, Tanya M., Williamson, Jeff D., Powell, Bayard L., and Kritchevsky, Stephen B.
- Subjects
- *
PATIENTS , *ACADEMIC medical centers , *GERIATRIC assessment , *ANALYSIS of variance , *CANCER chemotherapy , *CANCER patients , *COGNITION , *MENTAL depression , *EMOTIONS , *GRIP strength , *LONGITUDINAL method , *SCIENTIFIC observation , *PROBABILITY theory , *RESEARCH funding , *T-test (Statistics) , *ACTIVITIES of daily living , *ACUTE myeloid leukemia , *DATA analysis software , *DESCRIPTIVE statistics , *PSYCHOLOGY - Abstract
Objectives To measure short-term changes in physical and cognitive function and emotional well-being of older adults receiving intensive chemotherapy for acute myeloid leukemia ( AML). Design Prospective observational study. Setting Single academic institution. Participants Individuals aged 60 and older with newly diagnosed AML who received induction chemotherapy (N = 49, mean age 70 ± 6.2, 56% male). Measurements Geriatric assessment ( GA) was performed during inpatient examination for AML and within 8 weeks after hospital discharge after induction chemotherapy. Measures were the Pepper Assessment Tool for Disability (activity of daily living, instrumental activity of daily living ( IADL), mobility questions), Short Physical Performance Battery ( SPPB), grip strength, Modified Mini-Mental State examination, Center for Epidemiologic Studies Depression Scale, and the Distress Thermometer. Changes in GA measures were assessed using paired t-tests. Analysis of variance models were used to evaluate relationships between GA variables and change in function over time. Results After chemotherapy, IADL dependence worsened (mean 1.4 baseline vs 2.1 follow-up, P < .001), as did mean SPPB scores (7.5 vs 5.9, P = .02 for total). Grip strength also declined (38.9 ± 7.7 vs 34.2 ± 10.3 kg, P < .001 for men; 24.5 ± 4.8 vs 21.8 ± 4.7 kg, P = .007 for women). No significant changes in cognitive function (mean 84.7 vs 85.1, P = .72) or depressive symptoms (14.0 vs. 11.3, P = .11) were detected, but symptoms of distress declined (5.0 vs 3.2, P < .001). Participants with depressive symptoms at baseline and follow-up had greater declines in SPPB scores those without at both time points. Conclusions Short-term survivors of intensive chemotherapy for AML had clinically meaningful declines in physical function. These data support the importance of interventions to maintain physical function during and after chemotherapy. Depressive symptoms before and during chemotherapy may be linked to potentially modifiable physical function declines. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
36. Fall-risk prediction in older adults with cancer: an unmet need.
- Author
-
Wildes, Tanya, Depp, Brittany, Colditz, Graham, Stark, Susan, and Wildes, Tanya M
- Subjects
- *
CANCER patients , *CROSS-sectional method , *CANCER treatment , *GERIATRIC assessment , *QUALITY of life , *NEUROTOXICOLOGY , *ACCIDENTAL fall prevention , *AGE distribution , *MEDICAL needs assessment , *QUESTIONNAIRES , *RESEARCH funding , *TUMORS , *PILOT projects , *PREDICTIVE tests - Abstract
Falls in older adults with cancer are more common than in noncancer controls, yet no fall-risk screening tool has been validated in this population. We undertook a cross-sectional pilot study of the Falls Risk Questionnaire (FRQ) in 21 adults aged ≥65 receiving systemic cancer therapy. Participants completed the FRQ, geriatric assessment measures, and a measure of fear-of-falling. The recruitment rate was 87.5 %, with 95.2 % completion of the FRQ and additional geriatric assessment and quality of life measures. The FRQ correlated significantly with the Timed Up and Go test (Pearson r 0.479, p = 0.028). In addition, the FRQ score correlated directly with fear-of-falling and inversely with QOL, particularly physical health and neurotoxicity subscales. In conclusion, the FRQ was feasible in older adults receiving cancer therapy and correlates with measures of physical performance, functional status, and fear-of-falling. The FRQ may prove to be a valuable fall-risk screening tool to implement fall-prevention interventions in this vulnerable population of older adults with cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
37. Socioeconomic status is independently associated with overall survival in patients with multiple myeloma.
- Author
-
Fiala, Mark A., Finney, Joseph D., Liu, Jingxia, Stockerl-Goldstein, Keith E., Tomasson, Michael H., Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
MULTIPLE myeloma , *SOCIAL status , *MORTALITY , *CONFIDENCE intervals , *STEM cell transplantation - Abstract
Population-based studies suggest that black patients with multiple myeloma (MM) have a higher mortality rate than white patients. However, other studies suggest that this disparity is related to socioeconomic status (SES) rather than race. To provide clarity on this topic, we reviewed 562 patients diagnosed with MM at our institution. Patients with high SES had a median overall survival (OS) of 62.8 months (95% confidence interval [CI] 43.1–82.6 months), compared to 53.7 months (45.2–62.3 months) and 48.6 months (40.4–56.8 months) for middle and low SES, respectively (p = 0.015). After controlling for race, age, year of diagnosis, severity of comorbidities, stem cell transplant utilization and insurance provider, patients with low SES had a 54% increase in mortality rate relative to patients with high SES. To support our findings, we performed a similar analysis of 45,505 patients with MM from the Surveillance, Epidemiology and End Results-18 (SEER) database. Low SES is independently associated with poorer OS in MM. [ABSTRACT FROM PUBLISHER]
- Published
- 2015
- Full Text
- View/download PDF
38. Eliminating radiotherapy to the contralateral retropharyngeal and high level II lymph nodes in head and neck squamous cell carcinoma is safe and improves quality of life.
- Author
-
Spencer, Christopher R., Gay, Hiram A., Haughey, Bruce H., Nussenbaum, Brian, Adkins, Douglas R., Wildes, Tanya M., DeWees, Todd A., Lewis, James S., and Thorstad, Wade L.
- Subjects
- *
CANCER treatment , *SQUAMOUS cell carcinoma , *CANCER radiotherapy , *HEAD & neck cancer treatment , *LYMPH nodes , *QUALITY of life , *PHARYNGEAL cancer - Abstract
BACKGROUND Radiation treatment volumes in head and neck squamous cell carcinoma (HNSCC) are controversial. The authors report the outcomes, patterns of failure, and quality of life (QOL) of patients who received treatment for HNSCC using intensity-modulated radiation therapy (IMRT) that eliminated the treatment of contralateral retropharyngeal lymph nodes (RPLNs) in the clinically uninvolved neck. METHODS A prospective institutional database was used to identify patients who had primary oral cavity, oropharyngeal, hypopharyngeal, laryngeal, and unknown primary HNSCC for which they received IMRT. There were 3 temporal groups (generations 1-3). Generation 1 received comprehensive neck IMRT with parotid sparing, generation 2 eliminated the contralateral high level II (HLII) lymph nodes, and generation 3 further eliminated the contralateral RPLNs in the clinically uninvolved neck. Patterns of failure and survival analyses were completed, and QOL data measured using the MD Anderson Dysphagia Inventory were compared in a subset of patients from generations 1 and 3. RESULTS In total, 748 patients were identified. Of the 488 patients who received treatment in generation 2 or 3, 406 had a clinically uninvolved contralateral neck. There were no failures in the spared RPLNs (95% confidence interval, 0%-1.3%) or in the high contralateral neck (95% confidence interval, 0%-0.7%). QOL data were compared between 44 patients in generation 1 and 51 patients in generation 3. QOL improved both globally and in all domains assessed for generation 3, in which reduced radiotherapy volumes were used ( P < .007). CONCLUSIONS For patients with locally advanced HNSCC, eliminating coverage to the contralateral HLII lymph nodes and contralateral RPLNs in the clinically uninvolved side of the neck is associated with minimal risk of failure in these regions and significantly improved patient-reported QOL. Cancer 2014;120:3994-4002. © 2014 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
39. A prospective trial comparing FDG- PET/ CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
- Author
-
Adkins, Douglas, Ley, Jessica, Dehdashti, Farrokh, Siegel, Marilyn J., Wildes, Tanya M., Michel, Loren, Trinkaus, Kathryn, and Siegel, Barry A.
- Subjects
- *
POSITRON emission tomography , *COMPUTED tomography , *CANCER treatment , *SQUAMOUS cell carcinoma , *TREATMENT effectiveness , *CETUXIMAB , *HEAD & neck cancer treatment , *FLUORODEOXYGLUCOSE F18 - Abstract
Computed tomography ( CT), the standard method to assess tumor response to cetuximab in incurable squamous cell carcinoma of the head and neck ( SCCHN), performs poorly as judged by the disparity between high disease control rate (46%) and short time to progression ( TTP) (70 days). F-18 fluorodeoxyglucose positron emission tomography ( FDG- PET)/ CT is an alternative method to assess tumor response. The primary objective of this prospective trial was to evaluate the metabolic response of target lesions, assessed as the change in maximum standardized uptake value ( SUVmax) on FDG- PET/ CT before and after 8 weeks (cycle 1) of cetuximab. Secondary objectives were to compare tumor response by CT ( RECIST 1.0) and FDG- PET/ CT ( EORTC criteria) following cycle 1, and determine TTP with continued cetuximab administration in patients with disease control by CT after cycle 1 but stratified for disease control or progression by FDG- PET/ CT. Among 27 patients, the mean percent change of SUVmax of target lesions after cycle 1 was −21% (range: +72% to −81%); by FDG- PET/ CT, partial response ( PR)/stable disease ( SD) occurred in 15 patients (56%) and progression in 12 (44%), whereas by CT, PR/ SD occurred in 20 (74%) and progression in 7 (26%). FDG- PET/ CT and CT assessments were discordant in 14 patients ( P = 0.0029) and had low agreement ( κ = 0.30; 95% confidence interval [ CI]: 0.12, 0.48). With disease control by CT after cycle 1, median TTP was 166 days ( CI: 86, 217) if the FDG- PET/ CT showed disease control and 105 days ( CI: 66, 159) if the FDG- PET/ CT showed progression ( P < 0.0001). Median TTP of the seven patients whose post cycle 1 CT showed progression compared to the 12 whose FDG- PET/ CT showed progression were similar (53 [ CI: 49, 56] vs. 61 [ CI: 50, 105] days, respectively). FDG- PET/ CT may be better than CT in assessing benefit of cetuximab in incurable SCCHN. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
40. Risk factors for and pre-medications to prevent cetuximab-induced infusion reactions in patients with squamous cell carcinoma of the head and neck.
- Author
-
Touma, Waseem, Koro, Sami S., Ley, Jessica, Wildes, Tanya M., Michel, Loren, Tao, Yu, and Adkins, Douglas
- Subjects
- *
CETUXIMAB , *INFUSION therapy , *CANCER treatment , *SQUAMOUS cell carcinoma , *HEAD & neck cancer treatment , *MONOCLONAL antibodies , *INTRAVENOUS therapy , *THERAPEUTICS - Abstract
Objectives Cetuximab, a chimeric monoclonal antibody, is the only targeted therapy approved for squamous cell carcinoma of the head and neck (SCCHN). Infusion reactions (IRs) occur in 6-18% of patients pre-medicated with diphenhydramine. Evidence for clinical risk factors for IRs is limited and the benefit of additional pre-medication to prevent IRs is unclear. Materials and methods A retrospective, single institution study of 243 SCCHN patients treated with cetuximab to evaluate potential risk factors for IRs and to assess the efficacy of additional pre-medications (nebulized albuterol and intravenous (IV) corticosteroids and/or H2-blockers) to decrease the risk of IR. Results IR (grades 1-4) and high grade (grades 3-4 only) IR occurred in 47 (19.3%) and 16 (6.6%) patients, respectively. Multivariate analysis identified Caucasian race (OR7.11, p=0.003), medication allergy (OR3.74, p=0.002), and blood eosinophils >3% (OR2.75, p=0.01) independently increased the risk of IR; Caucasian race (OR5.57, p=0.007) and medication allergy (OR4.10, p=0.0007) increased the risk of high grade IR. IR (grades 1-4) and high grade IR occurred in 31.8% and 22.7% pre-medicated with diphenhydramine alone. Univariate analysis identified albuterol, famotidine, and corticosteroids decreased the risk of high grade IR. Furthermore, there was a significant difference between the possible combinations of the pre-medications and the risk of high grade IR by Fisher Exact test (p=0.003) whereby the combination of albuterol, famotidine and corticosteroids was effective in preventing high grade IR. Thirty (64%) of the 47 patients who developed an IR were re-challenged and did not experience a recurrence of an IR. Conclusion These data may be used to identify patients at higher risk for cetuximab-induced IR who may be advised to not receive cetuximab or who may benefit from additional pre-medications to decrease the risk of a high grade IR. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
41. The characteristics and outcomes of patients with multiple myeloma dual refractory or intolerant to bortezomib and lenalidomide in the era of carfilzomib and pomalidomide.
- Author
-
Wang, Tzu-Fei, Ahluwalia, Rohan, Fiala, Mark A., Trinkaus, Kathryn M., Cox, Doug P., Jaenicke, Matthew, Moliske, Caitlin C., Carson, Kenneth R., Wildes, Tanya M., Tomasson, Michael H., Stockerl-Goldstein, Keith E., and Vij, Ravi
- Subjects
- *
MULTIPLE myeloma , *BORTEZOMIB , *RETROSPECTIVE studies , *WILCOXON signed-rank test , *RANDOMIZED controlled trials , *PROTEASOME inhibitors , *KAPLAN-Meier estimator - Abstract
Patients with multiple myeloma who are refractory or intolerant to both bortezomib and lenalidomide have a poor prognosis. Next-generation therapies carfilzomib and pomalidomide have shown promising activity in this dual refractory population. Here we describe the clinical characteristics and ascertain the effects of carfilzomib and pomalidomide on survival in this patient cohort. We retrospectively reviewed the records of 65 patients with dual refractory/intolerant myeloma diagnosed between January 2007 and May 2012 at a single institution. The median overall survival (OS) from the time patients became dual refractory/intolerant was 10.2 months. Patients who received carfilzomib or pomalidomide after they became dual refractory/intolerant had a better OS compared to those who did not (12.6 vs. 6.8 months, p = 0.03 by Wilcoxon test). Prospective randomized control trials are needed for confirmation. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
42. A 54-year-old man with a rash and pulmonary infiltrates.
- Author
-
Lawrence K, Hachem R, Wildes TM, Canizares M, Lawrence, Kevin, Hachem, Ramsey, Wildes, Tanya M, and Canizares, Maria
- Published
- 2008
- Full Text
- View/download PDF
43. Limitations to Receiving Allogeneic Hematopoietic Cell Transplantation for Treatment of Acute Myeloid Leukemia: A Large Multi-Center Prospective Longitudinal Observational Study.
- Author
-
Sorror, Mohamed L., Storer, Barry E., Gerds, Aaron T., Medeiros, Bruno C, Shami, Paul J., Galvin, John P., Adekola, Kehinde U., Luger, Selina M., Baer, Maria R., Rizzieri, David A, Wildes, Tanya M., Wang, Eunice S., Faderl, Stefan, Koprivnikar, Jamie L., Sekeres, Mikkael A., Mukherjee, Sudipto, Smith, Julie, Garrison, Mitchell, Kojouri, Kiarash, and Nyland, Jennifer E.
- Subjects
- *
ACUTE myeloid leukemia treatment , *HEMATOPOIETIC stem cell transplantation , *COMORBIDITY , *CANCER remission , *LONGITUDINAL method - Abstract
Introduction Older pts with AML often have significant comorbidities and other geriatric health problems, and the effect of these on the probability of receiving HCT is unknown. We designed a prospective, longitudinal, observational study of adult pts with AML dating from first presentation at one of 13 centers. We examined the effects of different variables on the probability to 1) survive long enough to receive HCT and 2) to receive HCT if such survival occurred. Methods We enrolled 695 pts (Table 1). Data on demographics, AML status, cytogenetic risks per European Leukemia Network (ELN), response, age, comorbidities per the HCT-comorbidity index (CI), function, frailty, geriatric assessment, cognition, Karnofsky performance status (KPS), QOL, social support, and depression were collected at enrollment and at 1, 3, 6, 9, 12, 18, and 24 months thereafter. We used competing risk Cox regression analyses, treating HCT as the event of interest and death without HCT as a competing risk, with staggered entry (left truncation) at time of consent. Associations between variables were assessed both at enrollment and over time. Results The overall rate of HCT at 9 months after enrollment was 43% (Figure 1) and 92% who received HCT did so by 9 months. In multivariate analyses, death without HCT (Table 2) was associated with augmented HCT-CI scores ≥5, age ≥50 years with those aged ≥70 years having the highest association, ELN intermediate or unfavorable risks, receiving low-intensity induction regimens, relapsed/refractory disease at enrollment, dependent status per ADL scores <14, and depression per PHQ-9. Among survivors (Table 3), low likelihood to receive HCT was associated with age ≥70 years, low ELN risk, low-intensity induction, poor KPS, and relapse after initial complete remission (CR); while pts with high-risk MDS, relapsed/refractory disease at enrollment, and CR after induction were more likely to receive HCT. Among pts aged ≥60 years, and after considering previous factors, impaired cognition and hearing had a lower likelihood to receive HCT. Conclusions Increasing age, comorbidity burden, ELN risk, low-intensity initial AML induction regimen, depression, and functional dependence increase risks of early mortality without HCT. In those who survived long enough to potentially receive HCT, age up to 69 years and/or multiple comorbidities were not found to be barriers to HCT, likely reflecting the widespread use of reduced-intensity conditioning regimens. The adverse impact of impairments in psychological health and function on survival and of impairments of cognition, geriatric health, and performance status on receipt of HCT emphasize the need for interventions that target these health limitations in conjunction with AML treatment to improve outcomes. Finally, the benefit of intensive vs. less-intensive induction therapies should be addressed with a randomized trial. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
44. From Surviving to Thriving: Older Adults Adapting and Coping after Hematopoietic Cell Transplant.
- Author
-
Miller, Kimberly A, Hill-Polerecky, Diane, Koll, Thuy, Semin, Jessica, Coburn, Rachel, Wildes, Tanya M., Estabrooks, Paul, and Jones, Katherine
- Subjects
- *
OLDER people , *SEMI-structured interviews , *NURSING interventions , *LITERARY adaptations , *HEMATOLOGIC malignancies - Abstract
Due to advances in treatment regimens and supportive care, there are a growing number of older adults with hematologic malignancies undergoing hematopoietic cell transplant (HCT). While these advances have improved overall survival for this population, patients continue to experience rapid decline in physical, emotional, social, and role functioning post-HCT. Nursing interventions can assist with returning to life activities, an important goal for older patients. Current literature on adaptation and coping post-HCT has focused on younger survivors. The purpose of this qualitative descriptive study is to describe the experience of returning to life activities in patients 60 years of age and older who were more than three months post-HCT. Of particular interest was how coping resources and strategies help older patients adapt and cope to limitations in physical, psychological, and cognitive limitations. Twenty English speaking adults 60 years and older with hematological malignancy 3 to 12 months post-HCT completed semi-structured interviews. Open-ended questions and probes were guided by the Transactional Model of Stress and Coping to explore adaptive functioning, coping resources, and coping strategies. An integrated grounded theory approach was used to code the textual data to identify themes. Saturation was reached when the interview generated no new substantial information. Eight allogeneic and twelve autologous HCT recipients participated in the interviews. Three main themes emerged from the interviews. Adaptive functioning: all participants described adapting to physical and psychological changes. Coping resources: family (95%) and the healthcare team (80%) helped participants overcome physical, psychological, and cognitive limitations. Coping strategies: participants reported using emotion-focused, problem-focused, and meaning-based coping strategies. Overall, engaging in life activities and social support were significant in the recovery of physical, psychological and cognitive function. Older HCT recipients are an understudied population at high risk for functional decline. Patient-centered information on how HCT treatment influences cognitive function, functional outcomes, and quality of life will have broad implications for patient education and development of interventions for HCT patients. The next phase of this study will use these findings to guide development of health promoting interventions that nurses and the healthcare team can implement to help HCT recipients return to life activities. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
45. Re: Disparities in Utilization of Autologous Hematopoietic Cell Transplantation for Treatment of Multiple Myeloma.
- Author
-
Fiala, Mark A., Finney, Joseph D., Stockerl-Goldstein, Keith E., Tomasson, Michael H., DiPersio, John F., Vij, Ravi, and Wildes, Tanya M.
- Subjects
- *
HEALTH equity , *MULTIPLE myeloma treatment , *CANCER patients , *SOCIAL status , *HEMATOPOIETIC stem cell transplantation , *MEDICAL statistics - Abstract
Costa et al. recently reported that racial disparities prevented nearly 40% of non-Hispanic blacks with multiple myeloma (MM) from undergoing stem cell transplantation (SCT), but the authors were unable to provide an explanation for the disparities because of limitations of their datasets. They hypothesized that socioeconomic status (SES) and/or insurance providers might account for the disparity. To examine the issue raised by Costa et al., we performed a secondary analysis using hierarchical multivariate logistic regression with data previously collected to determine if age at diagnosis, sex, SES, primary insurance provider at diagnosis, and comorbidity score help explain the racial disparities in SCT utilization. A model of race, age, sex, SES, insurance provider, and comorbidity score was the most accurate model in predicting stem cell utilization status ( χ 2 [12] = 193.859; P < .001; area under the curve = .837; P < .001). After controlling for the covariates, black patients were less likely to undergo SCT than white patients (adjusted odds ratio, .49; 95% confidence interval, .27 to .89; P = .013). In conclusion, we also observed racial disparities between black and white patients with MM in SCT utilization and these are not fully accounted for by the covariates age, sex, SES, insurance provider, and comorbidity score. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
46. Looking beyond the CRT paradigm: Why induction chemotherapy is worthy of pursuit.
- Author
-
Adkins, Douglas, Ley, Jessica, Michel, Loren, Wildes, Tanya M., Thorstad, Wade, Rich, Jason, and Nussenbaum, Brian
- Subjects
- *
SQUAMOUS cell carcinoma , *CANCER treatment , *ADJUVANT treatment of cancer , *CANCER chemotherapy , *DOCETAXEL , *META-analysis , *PATIENTS - Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.